Details for Patent: 8,329,648
✉ Email this page to a colleague
Which drugs does patent 8,329,648 protect, and when does it expire?
Patent 8,329,648 protects FARXIGA, BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in three NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-eight patent family members in twenty-five countries.
Summary for Patent: 8,329,648
| Title: | Methods for treating diabetes and reducing body weight |
| Abstract: | Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA.sub.1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. |
| Inventor(s): | Fineman; Mark (San Diego, CA), MacConell; Leigh (San Diego, CA), Taylor; Kristin (San Diego, CA) |
| Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) |
| Application Number: | 13/084,757 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,329,648
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-001 | Jan 8, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 | ⤷ Sign Up | ||||
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-001 | Jan 8, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE | ⤷ Sign Up | ||||
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-001 | Jan 8, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 | ⤷ Sign Up | ||||
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-002 | Jan 8, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE | ⤷ Sign Up | ||||
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-002 | Jan 8, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 | ⤷ Sign Up | ||||
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-002 | Jan 8, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,329,648
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006283517 | ⤷ Sign Up | |||
| Australia | 2011200663 | ⤷ Sign Up | |||
| Australia | 2013205769 | ⤷ Sign Up | |||
| Brazil | PI0615358 | ⤷ Sign Up | |||
| Canada | 2619426 | ⤷ Sign Up | |||
| China | 101291685 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
